|1.||De Clercq, Erik: 29 articles (11/2013 - 05/2002)|
|2.||Hostetler, Karl Y: 24 articles (01/2015 - 03/2003)|
|3.||Beadle, James R: 20 articles (01/2015 - 01/2004)|
|4.||Smee, Donald F: 17 articles (01/2015 - 05/2002)|
|5.||De Clercq, E: 17 articles (06/2007 - 02/2001)|
|6.||Snoeck, Robert: 14 articles (02/2013 - 11/2002)|
|7.||Kern, Earl R: 14 articles (12/2010 - 01/2003)|
|8.||Snoeck, R: 13 articles (02/2015 - 02/2000)|
|9.||Sidwell, Robert W: 11 articles (04/2008 - 05/2002)|
|10.||Andrei, Graciela: 9 articles (02/2013 - 10/2006)|
01/01/2011 - "Of the compounds tested, topically applied cidofovir was the most effective treatment of cutaneous vaccinia virus infections in immunosuppressed mice. "
02/01/2005 - "Minimal cytopathic changes were observed at concentrations of 0.02 and 0.05 mg of cidofovir/mL. Cidofovir at concentrations of 0.05 and 0.02 mg/mL abrogated the cytopathic effects attributable to FHV-1 infection and reduced viral titers from > or =10(14) TCID(50)/mL to < or =10(3.5) TCID50/mL. Cidofovir in vitro was highly efficacious against FHV-1 infection of a primary culture of FCE cells but had cytostatic effects on cultured cells."
09/01/2003 - "As further evidence of the protective efficacy of aerosolized cidofovir, we found that aerosol treatment before or after infection was highly protective in mice challenged intranasally with cowpox virus. "
04/01/1991 - "The most remarkable feature of HPMPC was that a single administration of the compound, even as late as 4 days after infection, conferred significant protection against HSV-1 or HSV-2 infection. "
01/01/2015 - "To test infectivity of virus released from EPCs cultured in the presence of cidofovir, cell culture supernatants were used as inoculum for a further course of infection in UT7/EpoS1 cells, indicating a significant reduction in viral infectivity at 500 μM cidofovir. "
|2.||Acquired Immunodeficiency Syndrome (AIDS)
06/01/2002 - "Because of first positive results in treatment of PML in patients with AIDS, therapy with cidofovir was started. "
10/01/1999 - "Out of 22 cases described in the literature, including these 2 cases, with a therapy of cidofovir in AIDS-associated PML, 16 patients improved under therapy, 2 remained stable, and only 4 patients still worsened fulminantly. "
03/01/1999 - "PML is a terrifying neurological complication which has been resistant to a number of drugs, but cidofovir is currently being studied in an AIDS Clinical Trials Group (ACTG 363) and a European study group; results to date are controversial. "
04/01/1996 - "This trial was designed to evaluate the safety and antiviral effects of cidofovir in patients with AIDS and asymptomatic shedding of human cytomegalovirus (HCMV) in semen with no evidence of end-organ HCMV disease and no prior anti-HCMV therapy. "
05/01/2008 - "For AIDS patients with PML or failing non-AIDS patients with neurologic deterioration, cidofovir can be considered. "
08/01/2003 - "Topical applications of cidofovir, an antiviral compound with activity against human papilloma virus, is effective in the majority of patients with perianal condylomata and is a valuable adjuvant to surgical treatment of these lesions."
04/01/2000 - "We conclude that intralesional cidofovir appears to be a promising new treatment for controlling--and perhaps at higher dosages curing--refractory laryngeal papillomas, while causing little or no injury to laryngeal structures."
08/01/2014 - "The purpose of this study was to determine whether formulation of the small molecule acyclic nucleoside, cidofovir (CDV), could lead to improved therapeutic endpoints following topical treatment of papillomas using the cottontail rabbit papillomavirus (CRPV)/rabbit model. "
03/01/2010 - "Intralesional cidofovir injection has been shown to be an effective an safe therapy for laryngeal papilloma and should be considered in those patients who experienced disease relapse."
07/01/2008 - "Although results of case series suggest that cidofovir may decrease the frequency and rapidity of papilloma regrowth, no blinded placebo-controlled studies have demonstrated efficacy. "
11/01/1999 - "Cidofovir has proved to be highly effective in treatment of CMV retinitis. "
05/01/1997 - "Intravitreal cidofovir has been shown to be a long acting and highly efficacious treatment for CMV retinitis; however decrease in IOP is an adverse effect. "
07/01/1996 - "Treatment and subsequent maintenance therapy of CMV retinitis with 20 micrograms intravitreally injected cidofovir, given at 5- to 6-week intervals, is highly effective, with only rare episodes of re-activation and progression."
07/28/2000 - "Although effective for the treatment of CMV retinitis, cidofovir has potential toxicity. "
04/01/1998 - "Cidofovir therapy is effective in delaying progression of CMV retinitis that had previously progressed using other anti-CMV therapies."
09/15/2004 - "Topical cidofovir is more effective than is parenteral therapy for treatment of progressive vaccinia in immunocompromised mice."
06/01/2004 - "Efficacy of cidofovir in a murine model of disseminated progressive vaccinia."
01/01/2009 - "Here, we report that a single-dose vaccination regimen comprised of Dryvax and an antiviral agent, cidofovir, could reduce vaccinia viral loads after vaccination and significantly control Dryvax vaccination side effects. "
01/01/2006 - "Cidofovir was found to have an EC50 of 20 microM and 32 microM against vaccinia and cowpox virus, respectively. "
01/01/2006 - "4-[(1,2-Dihydro-2-oxo-3H-indol-3-ylidene)amino]-N-(4,6-dimethylpyrimidin-2-yl) benzenesulphonamide and its derivatives were tested in vitro for antiviral activity against vaccinia and cowpox virus replication in human foreskin fibroblast (HFF) cells, and their activity was compared with cidofovir (CDV). "
|6.||Phosphonic Acids (Phosphonates)
|9.||Antiviral Agents (Antivirals)
|10.||cidofovir hexadecyloxypropyl ester
|1.||Highly Active Antiretroviral Therapy (HAART)